Aromatase inhibitors: development and current perspectives (Record no. 17348)

MARC details
000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220829092830.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220829b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 17634
Author Sayyad, Nusrat B.
245 ## - TITLE STATEMENT
Title Aromatase inhibitors: development and current perspectives
250 ## - EDITION STATEMENT
Volume, Issue number Vol.56(2), Apr-June
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Karnataka
Name of publisher, distributor, etc. Association of Pharmaceutical Teachers of India (APTI)
Year 2022
300 ## - PHYSICAL DESCRIPTION
Pagination 311-320p.
520 ## - SUMMARY, ETC.
Summary, etc. Aim: Breast cancer is one of the most common cancers among women, consistently<br/>elevated estrogen level in the blood associated with persistently in breast cancer found in<br/>many studies. The mechanisms of carcinogenesis whereby cancer is associated involved<br/>in the conversion of androgen to estrogen in the presence of enzyme aromatase. Materials<br/>and Methods: Aromatase is a (CYP19), a cytochrome P450, which is the enzyme that<br/>synthesizes estrogen. Aromatase which is expressed in higher concentration in breast<br/>play a pivotal role in the origin and progression of breast cancer.<br/>In situ inhibition of<br/>aromatase enzyme accomplished by the prevention of aromatase expression in breast<br/>cancer. Results: The success of aromatase inhibition could result in the suppression and<br/>progression of breast cancer. One of the ways to reduce the incidence of breast cancer by<br/>inhibiting estrogen biosynthesis in breast tissue. Aromatase inhibitor therapy is considered<br/>for second-line treatment in patients who fail anti-estrogen therapy. Conclusion: Several<br/>potent and selective aromatase inhibitors have been developed and used to treat breast<br/>cancer. Some of them have passed clinical trial phase II. Development in the field has<br/>encouraged us to review work on the Aromatase inhibitor.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4639
Topical term or geographic name entry element PHARMACEUTICS
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 17635
Co-Author Sabale, Prafulla M.
773 0# - HOST ITEM ENTRY
Place, publisher, and date of publication Bengluru Association of Pharmaceutical Teachers of India (APTI)
International Standard Serial Number 0019-5464
Title Indian journal of pharmaceutical education and research
856 ## - ELECTRONIC LOCATION AND ACCESS
URL https://www.ijper.org/sites/default/files/IndJPhaEdRes-56-2-311.pdf
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     School of Pharmacy School of Pharmacy Archieval Section 29/08/2022   2022-1415 29/08/2022 29/08/2022 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.